– A doença hepática gordurosa não-alcoólica (DHGNA) é a doença hepática mais prevalente no mundo.
– Nos Estados Unidos, a DHGNA já é a segunda causa de transplante hepático.
– O espectro da doença abrange desde a esteatose simples, que apresenta curso benigno, até esteato-hepatite não-alcoólica (EHNA), que pode progredir para cirrose e suas complicações.
■ Screening for nonalcoholic fatty liver disease – when, who and how?
Christoph G Dietrich, Monika Rau, Andreas Geier
World J Gastroenterol.2021, vol 27(35): 5803–5821
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475001/
■ Diabetic kidney disease, cardiovascular disease and non-alcoholic fatty liver disease: A news triumvirate?
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada
J Clin Med.2021, vol 10(9): 2040
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126096/
■ Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
Reshu Khandelwal, Anuradha S Dassanayake, Hari S Conjeevaram, Shivaram P Singh
World J Diabetes.2021, vol 12(9): 1479–1493
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472504/
■ Alcohol consumption in patients with nonalcoholic fatty liver diasease: yes, or no?
Adonis A. Protopapas, Evangelos Cholongitas, Lampros Chrysavgis, Konstantinos Tziomalos
Ann Gastroenterol.2021, vol 34(4): 476–486
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276351/
■ Bypass vs. sleeve e seus resultados na doença hepatica gordurosa não alcoólica: Qual a melhor técnica?
M B Goldoni, P R O Fontes, M M Guimarães et al
Clin Exp Hepatol 2020, vol 6 (1): 1-8
https://www.scielo.br/j/abcd/a/HcmMBML5g9jfvXgyWvZcf4J/?lang=pt
■ European ¨NAFLD Preparedness Index¨- Is Europe ready to meet the challenge of fatty liver disease?
Jeffrey V. Lazarus, Adam Palayew, Patrizia Carrieri et al
JHEP Rep.2021, vol 3(2): 100234
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937562/
■ Non-alcoholic fatty liver disease – a procoagulant condition?
Lucija Virović-Jukić, Sanja Stojsavljević-Shapeski, Jelena Forgač et al
, Michal Kukla, Ivana Mikolašević
Croat Med J.2021, vol 62(1): 25–33
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976878/
■ How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?Yana Geng, Klaas Nico Faber, Vincent E. de Meijer, Hans Blokzijl, Han Moshage
Hepatol Int.2021, vol 15(1): 21–35
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886759/
■ Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies?
Agostino Di Ciaula, Salvatore Passarella, Harshitha Shanmugam et al
Int J Mol Sci.2021, vol 22(10): 5375
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160908/
■ Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil
Tel: 33245518
CRMMG: 7026
Email: pfleite1873@gmail.com
Blog Internet Médica – www.internetmedica.com.br
Data: outubro 2021